The acceptability of resin therapy to patients attending a hospital lipid clinic.
Low dose cholestyramine ('Questran A') and colestipol ('Colestid Orange') were compared in a blinded two period crossover study of 55 patients attending a hospital lipid clinic. Colestipol was rated higher on a combined acceptability/palatability score. Both treatments reduced low density lipoprotein (LDL) cholesterol to a similar extent.
Iversen
S A
SA
Brighton Healthcare NHS Trust, Royal Sussex County Hospital.
Davidson
D
D
Davidson
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000837:Anion Exchange Resins / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D003084:Colestipol / Q000627:therapeutic use*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
D000837:Anion Exchange Resins; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D002792:Cholestyramine Resin; D003084:Colestipol